If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...

Without medicine, it was 310 mg/dL. When I was put on Praluent by injection once a month, my cholesterol went down to 182 mg/dL. Although I don’t have many side effects, it is very expensive.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, ...

Regeneron Pharmaceuticals, Inc. REGN reported fourth-quarter 2024 earnings per share (EPS) of $12.07, which beat the Zacks Consensus Estimate of $11.62. The company recorded an EPS of $11.86 in the ...

Regeneron records net product sales of Praluent in the United States and Sanofi does the same outside the country. SNY pays REGN a royalty on such sales. Regeneron records global net product sales ...

We and Sanofi equally share profits from sales within ... Across the rest of Regeneron's product portfolio, cholesterol meds Evkeeza and Praluent earned $126m and $242m of revenues respectively ...

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...